CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 62,197 enrolled
Drug / intervention
Empagliflozin +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT05465317
NCT05465317N/ACompleted
CompareCT.gov

Comparative Cardiovascular and Renal Effectiveness and Safety of Empagliflozin and Other SGLT2i in Patients With Type 2 Diabetes (T2D) With and Without Baseline Kidney Disease in the United States

Boehringer Ingelheim·observational·Posted Jul 19, 2022·Updated Sep 19, 2024

In Brief

An observational study evaluating Empagliflozin and Dipeptidyl Peptidate-4 inhibitors for Diabetes Mellitus, Type 2. Completed, enrolled 62,197 participants across 1 site.

Detailed Summary

The primary purpose of this research study is to determine the cardiovascular and renal effectiveness and safety of empagliflozin compared to dipeptidyl peptidase-4 inhibitors (DPP4i) in patients with Type 2 Diabetes Mellitus (T2DM) with and without established kidney disease. The secondary purpose of this research study is to determine the cardiovascular and renal effectiveness and safety of any Sodium glucose co-transporter-2 inhibitors (SGLT2i) compared to Glucagon-like Peptide-1 Receptor Agonists (GLP1RA) in patients with T2DM.

Study Details

Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsDiabetes Mellitus, Type 2
CountriesUnited States
Collaborators--

Timeline

N/ACompletedFinished
2023202420252026
First PostedJul 19, 2022
Enrollment StartAug 8, 2022
Primary CompletionMay 2, 2023
TodayJul 2, 2026
Enrollment to primary: 9 monthsPosted 4.0 years ago

Interventions

Empagliflozindrug

Empagliflozin

Dipeptidyl Peptidate-4 inhibitorsdrug

Dipeptidyl Peptidate-4 inhibitors